SSKN - Strata Skin Sciences Inc Stock Price, Fair Value and News

0.51USD-0.02 (-3.77%)Market Closed

Market Summary

USD0.51-0.02

Market Closed

-3.77%

SSKN Stock Price

View Fullscreen

SSKN RSI Chart

SSKN Valuation

Market Cap

18.6M

Price/Earnings (Trailing)

-1.72

Price/Sales (Trailing)

0.56

EV/EBITDA

-7.97

Price/Free Cashflow

-3.36

SSKN Price/Sales (Trailing)

SSKN Profitability

Operating Margin

55.34%

EBT Margin

-32.74%

Return on Equity

-85.36%

Return on Assets

-25.78%

Free Cashflow Yield

-29.8%

SSKN Fundamentals

SSKN Revenue

Revenue (TTM)

33.4M

Rev. Growth (Yr)

-18.04%

Rev. Growth (Qtr)

-1.84%

SSKN Earnings

Earnings (TTM)

-10.8M

Earnings Growth (Yr)

-2.3K%

Earnings Growth (Qtr)

-260.3%

Breaking Down SSKN Revenue

Last 30 days

15.2%

Last 90 days

1.9%

Trailing 12 Months

-44.8%

How does SSKN drawdown profile look like?

SSKN Financial Health

Current Ratio

1.28

Debt/Equity

1.19

Debt/Cashflow

-0.03

SSKN Investor Care

Shares Dilution (1Y)

0.51%

Diluted EPS (TTM)

-0.31

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	36.7M	35.8M	35.3M	33.4M
2022	31.2M	32.9M	34.6M	36.2M
2021	22.2M	25.5M	27.6M	30.0M
2020	30.8M	27.1M	25.3M	23.1M
2019	30.6M	30.9M	30.7M	31.6M
2018	31.2M	30.2M	30.4M	29.9M
2017	30.4M	31.1M	30.8M	31.8M
2016	26.0M	33.2M	32.6M	30.7M
2015	898.2K	1.3M	9.4M	18.5M
2014	489.5K	570.1K	680.4K	914.8K
2013	410.9K	479.5K	518.1K	536.0K
2012	0	0	0	278.0K
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Strata Skin Sciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 01, 2023	gov shmuel	bought	8,955	0.447781	20,000	coo
Nov 16, 2023	rubinstein samuel	sold	-320	0.32	-1,000	-
Aug 16, 2023	22nw, lp	bought	1,023,070	0.5521	1,853,060	-
Aug 10, 2023	lesovitz christopher	bought	10,152	0.6701	15,151	chief financial officer
Aug 10, 2023	moccia robert joseph	bought	28,308	0.674	42,000	chief executive officer
Jul 05, 2023	walker patricia s	acquired	37,500	1.03	36,408	-
Jul 05, 2023	strang douglas	acquired	35,000	1.03	33,981	-
Jul 05, 2023	rubinstein samuel	acquired	35,000	1.03	33,981	-
Jul 05, 2023	shamir nachum	acquired	40,000	1.03	38,835	-
Jul 05, 2023	humphries william d.	acquired	37,500	1.03	36,408	-

Which funds bought or sold SSKN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Chicago Partners Investment Group LLC	sold off	-100	-33,396	-	-%
Apr 25, 2024	Allworth Financial LP	unchanged	-	-9.00	21.00	-%
Apr 24, 2024	Carmichael Hill & Associates, Inc.	unchanged	-	-517	1,134	-%
Apr 19, 2024	AZZAD ASSET MANAGEMENT INC /ADV	added	289	15,864	25,326	-%
Mar 22, 2024	PNC Financial Services Group, Inc.	sold off	-100	-18,881	-	-%
Mar 11, 2024	VANGUARD GROUP INC	unchanged	-	-38,533	472,097	-%
Mar 04, 2024	VIMA LLC	new	-	28.00	28.00	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	100	33,361	72,646	-%
Feb 15, 2024	Nantahala Capital Management, LLC	added	91.62	1,498,930	3,441,570	0.10%
Feb 14, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	sold off	-100	-14,348	-	-%

Are Funds Buying or Selling SSKN?

Are funds buying SSKN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SSKN

No. of Funds

Unveiling Strata Skin Sciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	nantahala capital management, llc	8.9%	3,128,132	SC 13G/A
Aug 18, 2023	22nw fund, lp	15.4%	5,369,954	SC 13G/A
Feb 14, 2023	nantahala capital management, llc	12.7%	4,393,685	SC 13G/A
Feb 13, 2023	22nw fund, lp	9.9%	3,439,261	SC 13G/A
Feb 14, 2022	nantahala capital management, llc	13.3%	4,575,812	SC 13G/A
Jan 14, 2022	22nw fund, lp	5.8%	2,002,059	SC 13G
Feb 16, 2021	kent lake capital llc	4.9%	1,658,043	SC 13G/A
Feb 12, 2021	nantahala capital management, llc	13.9%	4,683,908	SC 13G/A
Jun 23, 2020	broadfin capital, llc	4.54%	0	SC 13D/A
Jun 10, 2020	nantahala capital management, llc	13.9%	4,685,062	SC 13G/A

Recent SEC filings of Strata Skin Sciences Inc

View All Filings

Date Filed	Form Type	Document
Mar 28, 2024	10-K	Annual Report
Mar 27, 2024	8-K	Current Report
Feb 26, 2024	8-K	Current Report
Feb 21, 2024	8-K	Current Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Strata Skin Sciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	185.5B	40.1B	-4.14%	-1.72%	32.41	4.62	-8.12%	-17.45%
BDX	66.6B	19.5B	-4.72%	-10.85%	53.01	3.42	4.02%	-22.04%
ALGN	23.3B	3.9B	-2.96%	-12.43%	52.39	6.04	3.42%	23.09%
BAX	20.4B	14.8B	-3.18%	-12.72%	7.69	1.38	2.12%	209.17%
MID-CAP
HSIC	9.4B	12.3B	-0.07%	-10.32%	22.5	0.76	-2.44%	-22.68%
ATR	9.3B	3.5B	-1.98%	21.26%	32.53	2.65	4.97%	18.89%
BIO	8.0B	2.7B	-19.10%	-36.82%	-12.63	3.01	-4.68%	82.43%
XRAY	6.3B	4.0B	-6.58%	-25.82%	-46.81	1.59	1.10%	85.84%
AXNX	3.4B	366.4M	-3.44%	15.93%	-559.2	9.26	33.86%	89.83%
PDCO	2.3B	6.6B	-4.62%	-2.20%	11.94	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-14.98%	-16.46%	-1.88	0.4	7.73%	-1066.14%
ANIK	379.9M	166.7M	0.99%	-2.77%	-4.6	2.28	6.67%	-456.34%
ANGO	231.5M	324.0M	7.22%	-30.16%	-1.2	0.71	-3.19%	-337.41%
APYX	51.3M	52.3M	13.28%	-50.68%	-2.74	0.98	17.61%	19.28%
AEMD	3.9M	3.7M	-14.29%	284.62%	-0.32	1.05	5.77%	8.23%

Strata Skin Sciences Inc News

Latest updates

Strata Skin Sciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-1.8%	8,689	8,852	8,250	7,567	10,602	9,413	9,105	7,041	9,057	7,711	7,382	5,827	6,717	5,613	4,030	6,730	8,898	7,480	7,725	7,483	8,000
Cost Of Revenue	-0.3%	3,888	3,898	3,932	3,179	3,754	3,614	4,112	2,913	3,057	2,335	2,621	2,114	2,176	2,383	2,066	2,331	2,772	2,855	2,815	2,874	2,743
Gross Profit	-3.1%	4,801	4,954	4,318	4,388	6,848	5,799	4,993	4,128	6,000	5,376	4,761	3,713	4,541	3,230	1,964	4,399	6,126	4,625	4,910	4,609	5,257
Costs and Expenses	48.0%	8,242	5,569	6,280	6,974	6,714	6,585	6,687	6,431	6,622	5,841	5,684	6,105	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	6,622	5,841	5,684	6,105	4,893	4,391	3,579	5,347	6,183	5,354	5,893	5,850	5,324
S&GA Expenses	-9.2%	2,760	3,038	3,416	3,742	3,785	3,754	4,146	3,616	3,719	3,295	3,160	2,932	2,592	2,051	1,442	2,953	3,092	2,887	2,958	3,066	2,888
R&D Expenses	53.2%	380	248	374	315	441	216	209	163	276	371	403	384	324	411	247	292	214	249	235	304	234
EBITDA Margin	-290.6%	-0.10*	0.05*	0.04*	0.03*	0.03*	-0.02*	-0.01*	0.07*	0.05*	0.02*	0.00*	-0.11*	-0.01*	-	-	-	-	-	-	-	-
Interest Expenses	0%	528	528	298	286	275	244	208	199	205	53.00	26.00	30.00	249	-21.00	-18.00	1.00	-82.00	-153	-145	-135	212
Income Taxes	-	-	-	-	-	63.00	-	-	-	22.00	4.00	4.00	4.00	68.00	72.00	47.00	88.00	-38.00	-22.00	-46.00	-43.00	-264
Earnings Before Taxes	-	-	-	-	-	-97.00	-995	-1,892	-2,502	-827	-517	1,086	-2,414	-375	-1,182	-1,633	-947	-553	-882	-1,128	-1,376	21.00
EBT Margin	-110.5%	-0.33*	-0.16*	-0.15*	-0.15*	-0.15*	-0.18*	-0.17*	-0.09*	-0.09*	-0.08*	-0.11*	-0.25*	-0.18*	-	-	-	-	-	-	-	-
Net Income	-260.3%	-3,794	-1,053	-3,148	-2,835	-160	-995	-1,892	-2,502	-849	-521	1,082	-2,418	-443	-1,254	-1,680	-1,035	-515	-860	-1,082	-1,333	285
Net Income Margin	-59.1%	-0.32*	-0.20*	-0.20*	-0.16*	-0.15*	-0.18*	-0.18*	-0.09*	-0.09*	-0.08*	-0.12*	-0.26*	-0.19*	-	-	-	-	-	-	-	-
Free Cashflow	81.0%	-347	-1,826	-756	-2,609	-1,520	-1,221	-887	-1,032	-461	-605	-492	-587	-366	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-11.0%	42.00	47.00	55.00	49.00	52.00	53.00	54.00	55.00	47.00	47.00	45.00	46.00	47.00	47.00	46.00	46.00	47.00	48.00	48.00	48.00	48.00
Current Assets	-21.2%	16.00	20.00	21.00	15.00	15.00	19.00	19.00	19.00	20.00	20.00	23.00	24.00	25.00	25.00	24.00	23.00	24.00	24.00	24.00	24.00	23.00
Cash Equivalents	-4.9%	7.00	7.00	9.00	3.00	5.00	7.00	10.00	11.00	13.00	13.00	10.00	10.00	18.00	11.00	11.00	8.00	16.00	16.00	16.00	16.00	16.00
Inventory	-56.4%	3.00	6.00	6.00	6.00	3.00	6.00	5.00	5.00	3.00	3.00	3.00	3.00	3.00	4.00	3.00	3.00	3.00	4.00	4.00	3.00	3.00
Net PPE	42.7%	12.00	8.00	8.00	8.00	10.00	7.00	7.00	7.00	7.00	6.00	6.00	6.00	6.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
Goodwill	-25.9%	7.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00
Liabilities	-5.4%	29.00	31.00	38.00	30.00	30.00	31.00	31.00	31.00	21.00	21.00	19.00	22.00	21.00	21.00	19.00	18.00	19.00	19.00	19.00	18.00	16.00
Current Liabilities	1.2%	12.00	12.00	14.00	13.00	13.00	14.00	14.00	14.00	13.00	12.00	18.00	20.00	19.00	19.00	17.00	17.00	17.00	12.00	11.00	10.00	9.00
Long Term Debt	0.2%	15.00	15.00	15.00	8.00	7.00	7.00	7.00	7.00	7.00	7.00	0.00	1.00	1.00	1.00	2.00	-	-	5.00	6.00	6.00	7.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	0.00	2.00	1.00	1.00	1.00	-	-	3.00	2.00	1.00	0.00
LT Debt, Non Current	0.2%	15.00	15.00	15.00	8.00	7.00	7.00	7.00	7.00	7.00	7.00	0.00	1.00	1.00	1.00	2.00	-	-	5.00	6.00	6.00	7.00
Shareholder's Equity	-21.6%	13.00	16.00	17.00	19.00	22.00	22.00	22.00	24.00	25.00	26.00	26.00	24.00	26.00	26.00	27.00	28.00	29.00	29.00	29.00	30.00	31.00
Retained Earnings	-1.6%	-238	-234	-233	-230	-227	-227	-226	-224	-221	-220	-220	-221	-218	-218	-217	-215	-214	-214	-213	-212	-210
Additional Paid-In Capital	0.1%	251	250	250	249	249	249	248	248	247	247	246	245	245	244	244	244	243	243	243	242	242
Shares Outstanding	0.4%	35.00	35.00	35.00	35.00	35.00	35.00	35.00	35.00	34.00	34.00	34.00	34.00	34.00	-	-	-	-	-	-	-	-
Float	-	-	-	17.00	-	-	-	17.00	-	-	-	26.00	-	-	-	24.00	-	-	-	49.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	251.1%	1,506	-997	175	-1,203	179	-694	-56.00	-353	669	452	234	153	346	549	603	598	1,113	710	70.00	336	1,101
Share Based Compensation	-14.2%	289	337	352	325	191	455	452	368	80.00	320	581	662	357	403	410	430	312	257	303	323	334
Cashflow From Investing	-123.5%	-1,853	-829	-931	-1,406	-1,699	-527	-831	-1,310	-1,130	-4,530	-726	-740	-712	-717	-134	-596	-1,416	-423	-518	-434	-502
Cashflow From Financing	100.0%	-	-104	-	-	-500	-	-	-	-	92.00	-	-	18.00	-	-	-	-296	-	-	-	-

SSKN Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Consolidated Statements of Operations [Abstract]
Revenues, net	$ 33,358	$ 36,161
Cost of revenues	14,897	14,393
Gross profit	18,461	21,768
Operating expenses:
Engineering and product development	1,317	1,029
Selling and marketing	12,956	15,301
General and administrative	10,508	10,087
Impairment of goodwill	2,284	0
Total operating expenses	27,065	26,417
Loss from operations	(8,604)	(4,649)
Other (expense) income:
Interest expense	(1,640)	(926)
Interest income	231	89
Loss on debt extinguishment	(909)	0
Other (expense), income net	(2,318)	(837)
(Loss) income before benefit from / (provision for) income taxes	(10,922)	(5,486)
Benefit from / (provision for) income taxes	92	(63)
Net loss	$ (10,830)	$ (5,549)
Net loss per share of common stock - basic (in dollars per share)	$ (0.31)	$ (0.16)
Net loss per share of common stock - diluted (in dollars per share)	$ (0.31)	$ (0.16)
Weighted average shares of common stock outstanding - basic (in shares)	34,920,291	34,712,246
Weighted average shares of common stock outstanding - diluted (in shares)	34,920,291	34,712,246

SSKN Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 6,784	$ 5,434
Restricted cash	1,334	1,361
Accounts receivable, net of allowance for credit losses of $222 and $382 at December 31, 2023 and 2022, respectively	4,440	4,471
Inventories	2,673	3,095
Prepaid expenses and other current assets	312	691
Total current assets	15,543	15,052
Property and equipment, net	11,778	9,950
Operating lease right-of-use assets	626	975
Intangible assets, net	7,319	17,394
Goodwill	6,519	8,803
Other assets	231	98
Total assets	42,016	52,272
Current liabilities:
Accounts payable	3,343	3,425
Accrued expenses and other current liabilities	6,306	6,555
Deferred revenues	2,120	2,778
Current portion of operating lease liabilities	352	355
Current portion of contingent consideration	53	313
Total current liabilities	12,174	13,426
Long-term debt, net	15,044	7,476
Deferred revenues and other liabilities	552	314
Deferred tax liability	186	306
Operating lease liabilities, net of current portion	237	610
Contingent consideration, net of current portion	1,135	8,309
Total liabilities	29,328	30,441
Commitments and contingencies (Note 11)
Stockholders' equity:
Series C convertible preferred stock, $0.10 par value; 10,000,000 shares authorized, no shares issued and outstanding	0	0
Common stock, $0.001 par value; 150,000,000 shares authorized; 35,060,920 and 34,723,046 shares issued and outstanding at December 31, 2023 and 2022, respectively	35	35
Additional paid-in capital	250,711	249,024
Accumulated deficit	(238,058)	(227,228)
Total stockholders' equity	12,688	21,831
Total liabilities and stockholders' equity	$ 42,016	$ 52,272

About Strata Skin Sciences Inc

STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. The company products include XTRAC and Pharos excimer lasers, and VTRAC lamp systems for the treatment systems that are used for the treatment of psoriasis, vitiligo, and other skin conditions. It also provides TheraClear Acne Therapy System for the treatment of mild to moderate inflammatory, comedonal, and pustular acne. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.

CEO	Mr. Robert J. Moccia
WEBSITE	strataskinsciences.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	114

Strata Skin Sciences Inc Frequently Asked Questions

What is the ticker symbol for Strata Skin Sciences Inc? What does SSKN stand for in stocks?

SSKN is the stock ticker symbol of Strata Skin Sciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Strata Skin Sciences Inc (SSKN)?

As of Thu Apr 25 2024, market cap of Strata Skin Sciences Inc is 18.58 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SSKN stock?

You can check SSKN's fair value in chart for subscribers.

What is the fair value of SSKN stock?

You can check SSKN's fair value in chart for subscribers. The fair value of Strata Skin Sciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Strata Skin Sciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SSKN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Strata Skin Sciences Inc a good stock to buy?

The fair value guage provides a quick view whether SSKN is over valued or under valued. Whether Strata Skin Sciences Inc is cheap or expensive depends on the assumptions which impact Strata Skin Sciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SSKN.

What is Strata Skin Sciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 25 2024, SSKN's PE ratio (Price to Earnings) is -1.72 and Price to Sales (PS) ratio is 0.56. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SSKN PE ratio will change depending on the future growth rate expectations of investors.